HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

Exclusion criteria

• ✕. Karnofsky performance score less than 70%.
• ✕. Participant is known to have an HIV subtype other than B.
• ✕. Participant has documented raltegravir or protease inhibitor resistance.
• ✕. Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
• ✕. Uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression or no clinical improvement).
• ✕. Participant has active CNS involvement.
• ✕. Participants with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent greater than or equal to 5 years previously will be allowed. Cancer treated with curative intent less than 5 years BMT CLINICAL TRIALS NETWORK HIV T-Cell - Protocol 1903 Version 1.0 Dated February 24, 2021 2-4 Confidential previously may be eligible must be reviewed and approved by the Protocol Officer or Chairs.
• ✕. Female participants that are pregnant as per institutional definition or breastfeeding.